- Parties: The appellant was Samsung Bioepis Co., Ltd. The respondents were Novartis AG and Novartis Pharmaceuticals Canada Inc.

- Subject Matter: This appeal challenged the application judge's judgment, which ordered a permanent injunction against the appellant and others to prohibit them from using the BYOOVIZ trademark in association with pharmaceutical preparations for use in opthalmology or for prevention and treatment of ocular disorders and diseases or any other trademark or trade name confusingly similar to the registered BEOVU trademark. This case is ongoing.

- Date: The hearing was set on May 28, 2024.

- Venue: This was a federal case before the Federal Court of Appeal.

- Amount: No financial award was specified.